by Welsh Assembly Government / Llywodraeth Cymru

Australia Pharmaceutical Market Overview – Reforms and continued price cuts will change the healthcare landscape now available at ReportsandReports

The prescription pharmaceutical market in Australia was valued at .1 billion in 2009. Key growth drivers include the growing use of chronic high-value innovative treatments driven by a rising elderly population and high public spending as a proportion of total healthcare expenditure.

Scope

* Overview of Australia’s socioeconomics and demographics, healthcare system, regulation, pricing and reimbursement and intellectual property position.

* Assesses the size of Australia’s pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies.

* Examines Australia’s generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion.

* Quantifies Australia’s R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A

by Office of Governor Patrick

China’s Pharmaceutical Actuality and Future

Only two decades ago, China was a poor agricultural country; now it becomes the third-largest economy in the world, with a GDP of more than , 108 billion in 2006. Experts forecast that by 2020, China will be the world’s largest economy.

1, China’s pharmaceutical market

The has shown impressive growth in recent years, in tandem with the country’s rapid economic expansion. In the past twenty years, China’s pharmaceutical market has an averaging between 18 – 20% growth, significantly higher than US and European growth during that period (7 – 9%). The total pharmaceutical market is expected to grow to .7 billion by the year 2005, to become the world’s largest pharmaceutical market by 2020.

2, China’s pharmaceutical industry

China has a large domestic pharmaceutical industry, providing 80% of China’s pharmaceutical consumption. In 1995, approximately 3,000 domestic state pharmaceutical enterprises produced a total

by ludwig van standard lamp

China Pharmaceutical Industry to grow at 12.5% CAGR by 2014

Emerging Markets Direct (EMD) released the latest China Pharmaceutical Industry Report1H11. China Pharmaceutical market has been growing rapidly as the fourth-largest market in the world in terms of size.  As one of the “pharmerging markets” in BRIC, the industry is expected to grow at 12.5% CAGR during 2009 – 2014. Backed by vast pool of talent, low-cost manufacturing capabilities, and huge market potential, it has attracted several global drug giants to outsource their R&D and invest in China.

While the market size of China Pharmaceuticals in 2009 was USD46.15billion, its overall health expenditure was among the lowest in the world comparable to that of Morocco, India or Saudi Arabia. In 2009, China’s overall health expenditure was at USD230.7 billion, a 4.7% of total GDP.  The industry is well-known for its fragmented nature with 7,664 enterprises in 2009, out of which local domestic enterprises account for 70% of industry sales.

Government policies

by Carmen Alonso Suarez

Patents and Ethics in the Pharmaceutical Industry

Abstract

This paper is concerned with the impacts of strict patents in the pharmaceutical industry, focusing on the Trade Related Aspects of Intellectual Property Rights (TRIPs) Agreement. It discusses the historical and current policy context, to better understand how strict patents affect the availability of essential drugs in developing countries.

The research shows that the pharmaceutical industry prioritises profit above health. Strict patents reduce the availability and affordability of new essential drugs in developing countries, and thereby have a negative impact on the health of the world’s poor. Larger pharmaceutical companies benefit more than smaller companies because they have a monopoly in the industry. They invest more in research and development and, linked to economies of scale, are better positioned to exploit markets for new drugs.

The example of India highlights the importance of generic production